Study drug for hard-to-treat multiple myeloma after prior treatments
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older when you sign consent
- Have multiple myeloma that has been confirmed by a specialist using standard diagnostic criteria
- Have had at least 3 prior treatment “lines,” including a proteasome inhibitor, an immune-modulating drug, and an anti-CD38 antibody
- Your disease must be getting worse (progressive disease) based on standard criteria, and you must have measurable disease at screening
- Your body must be strong enough for study treatment (generally ECOG 0–1) and your blood, liver, and kidney tests must meet limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a lab-made immune cell therapy (CAR-T) made from a donor, with a CRISPR edit, for multiple myeloma that has come back or not responded to treatment. It aims to find the safest way to give the treatment and see how well it can control the cancer.
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests two new CAR-T cell therapies (LCAR-M61S and LCAR-M61D) for people whose multiple myeloma has come back or stopped responding to at least three prior treatments. The treatment uses your own immune cells that are modified to find and attack cancer cells.
This trial tests an experimental drug called JNJ-79635322 for people with multiple myeloma that has come back or hasn't responded to at least three previous treatments, including a PI, an IMiD, and a CD38-targeted antibody. The goal is to see if this new drug can help control the disease.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.